Post-earnings recap
Reported
Tue, May 8, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Arrowhead Pharmaceuticals reported a loss per share of $0.18, which was slightly below expectations. The stock reacted by declining 0.26%, indicating that investors may have been disappointed with the earnings report. Without additional commentary from management, it's difficult to assess the company's outlook moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.18 | N/A | -5.79% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.